Generic injectable-focused Gland Pharma’s consolidated net profit declined 3% for the March quarter to ₹186.5 crore from ₹192.4 crore year earlier on the back of lower sales in the key U.S. as well as Rest of the World (RoW) markets.
The net profit came on 7% decline in revenue from operations to ₹1,424.9 crore (₹1,537.5 crore). Sales in the U.S. market was 10% lower at ₹791.8 crore (₹878.4 crore), while it fell 14% in the RoW market to ₹240.4 crore (₹280.2 crore). The company reported higher sales revenue from Europe; as well as Canada, Australia and New Zealand markets and static growth in the India market.
For 2024-25, Gland Pharma reported 10% decline in net profit to ₹698.5 crore ₹772.5 crore on 1% drop in revenue from operations to ₹5616.5 crore (₹5664.7 crore).
₹18 dividend
The company has declared a dividend of ₹18 per equity share (face value of ₹1 each) for FY-25.
“Looking ahead, our strategic focus is on accelerating growth in RoW and India, deepening our U.S. presence through portfolio enhancement and continuing to lead on quality and cost efficiency,” CEO Shyamakant Giri said in a release on the March results.
Executive Chairman Srinivas Sadu said strategic realignment and investment in future growth market were the highlights of FY25. “Our approach involves expanding our core business into new emerging markets, carefully enhancing our manufacturing capabilities to encompass complex injectables and novel delivery systems and building pipeline through our robust in-house research and development efforts,” he said.
Published – May 20, 2025 10:05 pm IST
